A comparison of two medical-biomedical and genetics stocks reveals that Incyte (INCY) is the more attractive value investment option. INCY holds a Zacks Rank #2 (Buy) with improving earnings outlook and a Value grade of B, while Techne (TECH) has a Zacks Rank #3 (Hold) and Value grade of D. INCY's lower PEG ratio (2.67 vs 7.53) and P/B ratio (3.94 vs 5.38) suggest better valuation metrics.

Bio-Techne (TECH) reported Q4 adjusted EPS of 52 cents, meeting consensus estimates but declining 1.9% year-over-year. Full-year adjusted EPS of $1.93 increased 0.5% and surpassed consensus by 1%. Q4 revenues of $321.2 million exceeded estimates by 1.26%, though organic growth was modest at 3%. The company improved its balance sheet with cash increasing to $264.7 million and debt declining to $200 million. However, analysts have issued no estimate revisions in the past two months, and the stock carries a Zacks Rank #3 (Hold) with weak growth and momentum scores.

Monteverde & Associates PC is investigating four major merger and acquisition deals to determine if they are fair to shareholders: Auddia's merger with McCarthy Finney (1:1 stock exchange), Bio-Techne's sale to Merck KGaA ($73/share), Caesars Entertainment's sale to Fertitta Gaming ($31/share plus ticking consideration), and Colony Bankcorp's merger with First Reliance Bancshares ($19.75 cash or 0.94 stock exchange).

The global multiplex assays market is projected to grow from US$6.8 billion in 2025 to US$12.4 billion by 2030, at a 12.8% CAGR. North America leads with 34% market share, while Asia Pacific is the fastest-growing region at 15.5% CAGR. Consumables dominate with 68% market share, and protein multiplex assays hold 42%. Growth is driven by precision medicine, companion diagnostics, and laboratory automation.

Halper Sadeh LLC, an investor rights law firm, is investigating four companies for potential violations of federal securities laws and breaches of fiduciary duties related to their proposed acquisitions. The firm is examining whether shareholders are receiving fair consideration and whether insider benefits may be limiting superior competing offers.

Bio-Techne shares surged 20% after Merck KGaA announced a $73-per-share cash acquisition offer. The deal comes one week after activist investor Ananym Capital Management built a stake and pushed for a sale. Trading volume reached 51.3M shares, significantly above average. Merck KGaA expects to achieve over $150 million in annual cost synergies within three years.

U.S. equities hit fresh record highs on May 6, 2026, with the S&P 500 and Nasdaq 100 reaching all-time peaks. AMD and Super Micro Computer surged 16% on strong AI-driven earnings, while oil prices collapsed 6-7% on diplomatic hopes between Washington and Tehran. Technology stocks led gains, though energy stocks declined sharply. Mixed earnings results saw winners like Flex Ltd. (+30%) and DaVita (+18%), while CDW and Coupang fell 20% and 17.5% respectively.

The global ELISpot & FluoroSpot assay market is projected to grow at a CAGR of 7.1% from 2025 to 2031, driven by increasing adoption of immunology research techniques, personalized immune therapies, and advanced diagnostic assays. Key growth areas include reagent products, pharmaceutical & biotechnology firms, and the APAC region. Major trends include automation, multiplexing capabilities, and expanding applications in clinical diagnostics, vaccine development, and immuno-oncology.

Bio-Techne Corporation (NASDAQ: TECH) announced a quarterly dividend of $0.08 per share for the quarter ended December 31, 2025, payable on February 27, 2026, to shareholders of record on February 16, 2026. The company generated over $1.2 billion in net sales in fiscal 2025 and employs approximately 3,100 people worldwide.

The Middle East exosomes market is projected to grow from USD 3.07 million in 2024 to USD 20.03 million by 2033, at a CAGR of 23.38%. Growth is driven by increasing adoption of exosome-based diagnostics and therapeutics, rising biomedical R&D investment, and growing demand for liquid biopsy technologies. Key challenges include stringent regulatory requirements and high manufacturing costs.

Bio-Techne Corporation announced a quarterly dividend of $0.08 per share, payable on November 28, 2025, to shareholders of record on November 17, 2025. The global life sciences company generated over $1.2 billion in net sales in fiscal 2025.

MDxHealth has completed the acquisition of Exosome Diagnostics from Bio-Techne for $15 million, which includes the ExoDx Prostate test and related assets, with payments structured over four years.